BiotechTube
Home/Altay Therapeutics/Klaus Jensen, Ph.D.
KJ

Klaus Jensen, Ph.D.

DMPK

Altay Therapeutics

Therapeutic Areas

Muscular DystrophyOncologyInflammatory Diseases

Altay Therapeutics Pipeline

DrugIndicationPhase
DX5057Facioscapulohumeral Muscular Dystrophy (FSHD)Preclinical
STAT3 InhibitorInflammatory Diseases & OncologyLead Optimization
Undisclosed Oncology ProgramSarcomas and Prostate CancerLead Optimization

Leadership Team at Altay Therapeutics

MG
Mike Grey
Executive Chair, Board of Directors
EB
Eric Bjerkholt
Board of Directors
EC
Eva Chin, Ph.D.
Board of Directors
AO
Ali Ozes, Ph.D.
Founder & CEO, Board of Directors
ON
Osman N. Ozes, Ph.D.
Founder
AD
Alejandro Dorenbaum, M.D.
Chief Medical Officer
JB
Jason Brittain, Ph.D.
Drug Product
LL
Lee Latimer, Ph.D.
MedChem
NL
Noopur Liffick, MPH
Advisor
AL
Angela Lynch, Ph.D.
Toxicologist
View full Altay Therapeutics profile